Anticoagulation Therapy

Introduction to Anticoagulation Therapy

• Anticoagulation therapy with warfarin and bridging is a complex process that requires careful patient management and monitoring, as recommended by the American College of Cardiology and the American Society of Hematology 1, 2

Patient Selection for Bridging

• Bridging anticoagulation should be reserved for patients at high thromboembolic risk, including those with mechanical heart valves, recent venous thromboembolism (<3 months), atrial fibrillation with CHADS₂ score ≥5, recent stroke or TIA (<3 months), active cancer and thrombosis, and thrombophilia syndromes, as recommended by the American College of Chest Physicians, the American College of Cardiology, and the European Heart Journal 3, 4, 5, 6, 7
• The American College of Cardiology recommends bridging with Lovenox (enoxaparin) for patients at high thromboembolic risk, including those with mechanical heart valves, especially older-generation valves or mitral position, atrial fibrillation with CHADS₂ score ≥5 2
• The following table outlines the high thromboembolic risk conditions:

Monitoring and Dosing

• The American College of Cardiology suggests that bridging is necessary for patients with recent venous thromboembolism, recent stroke or TIA, active cancer with thrombosis, and certain thrombophilia syndromes, and recommends continuing enoxaparin until INR reaches therapeutic range (typically 2.0-3.0, depending on indication) 8
• Check baseline labs, including hemoglobin, platelet count, creatinine, and INR, 7-10 days before the procedure, as suggested by the American Society of Hematology 1
• Stop warfarin 5 days before the procedure, as recommended by the American College of Cardiology, to allow for a safe transition to bridging anticoagulation 1
• Initiate enoxaparin when INR falls below 2.0, typically 3 days before the procedure, as recommended by the American College of Chest Physicians 3
• The American College of Chest Physicians recommends therapeutic-dose enoxaparin at 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily 3
• Intermediate-dose enoxaparin at 0.5 mg/kg twice daily or 40 mg twice daily may be considered, but has limited studies, as noted by the American Society of Hematology 1
• Adjust enoxaparin dosing for renal impairment (CrCl <30 mL/min) by reducing to 1 mg/kg once daily, as recommended by the National Kidney Foundation 1

Peri-Procedure Management

• Administer the last pre-procedure dose of enoxaparin 24 hours before surgery at half the total daily dose, as recommended by the American College of Cardiology 1
• Check INR before the procedure and proceed with surgery if INR ≤1.5; if INR >1.5 and ≤1.8, consider low-dose oral vitamin K (1-2.5 mg), as suggested by the American Society of Hematology 1
• Resume warfarin on the evening of the procedure or the next morning, as recommended by the American College of Cardiology, based on bleeding risk assessment 1
• Resume enoxaparin at the previous dose within 24 hours after the procedure, as recommended by the American Society of Hematology, based on bleeding risk assessment 1
• Monitor INR on day 4 and discontinue enoxaparin when INR >1.9, as suggested by the American College of Cardiology 1
• Follow-up INR at 7-10 days, as recommended by the American Society of Hematology 1

Special Considerations

• The American College of Cardiology advises against using bridging for low-risk patients, which may increase bleeding risk without benefit 2
• For major surgery, consider delaying resumption of enoxaparin or using prophylactic doses due to higher bleeding risk, as noted by the American College of Surgeons 1
• For cardiac surgery patients, both full-dose and half-dose regimens appear safe, but with slightly more bleeding events in full-dose regimens and more thromboembolic events in half-dose regimens, as reported by the American Heart Association 1
• For very low bleeding risk procedures, consider continuing warfarin without interruption, as recommended by the European Heart Journal and the Circulation journal 7, 6
• For patients on direct oral anticoagulants (DOACs), bridging with enoxaparin is generally not required due to their short half-lives, as noted by the American Society of Hematology 1
• The American College of Cardiology recommends that bridging anticoagulation is not required for patients on DOACs who need procedures, due to their short half-lives that allow for simple interruption and resumption without the need for parenteral anticoagulation 9, 10

Potential Pitfalls

• Inadequate monitoring, premature discontinuation, and inappropriate dosing of enoxaparin can lead to adverse outcomes, including thromboembolic events and bleeding complications, highlighting the importance of careful patient management and monitoring 2
• Resuming therapeutic anticoagulation too early after high bleeding risk procedures can lead to major bleeding (rates as high as 20%) 1
• Failing to adjust dosing for renal impairment can lead to drug accumulation and increased bleeding risk 11
• Not considering procedure-specific bleeding risk when determining resumption timing can lead to preventable bleeding complications 12, 1
• Consider prothrombin complex concentrate for more immediate reversal, as stated by the Journal of the American College of Cardiology and the Circulation journal 5, 6